Aerial technology company EHang Holdings Limited has announced a new collaboration with Lung Biotechnology PBC to develop and purchase up to 1,000 units of an evolved version of the 184, the world's first autonomous drone for humans, to automate organ transplant delivery. The two companies have agreed to work together to optimize the 184 for organ deliveries, a programeme which they are calling the Manufactured Organ Transport Helicopter (MOTH) system.

EHang is an aerial technology company with headquarter in Guangzhou and branch offices in California, Duesseldorf, Beijing and Shanghai. It produces the GHOSTDRONE 2.0 and the recently launched EHang 184 Autonomous Aerial Vehicle (AAV), billed as the first vehicle to offer autonomous human flight over short-to-medium distances. Unveiled at CES 2016, the 184 will be capable of carrying a passenger more than 10 miles at speeds up to 65 miles per hour simply by entering a destination into its accompanying smartphone app.

Lung Biotechnology specializes in manufacturing lungs and other organs for transplant using a variety of technologies, including pig-to-human xenotransplantation, as well as regenerating them from stem cells. It plans to station the MOTH vehicles close to its organ manufacturing facilities, and use preprogrammed flight plans to hospitals and re-charging pads within the MOTH radius so that the manufactured organs can be delivered within their post-production window of viability.

MOTH purchases by Lung Biotechnology will be contingent upon successful development and U.S. Federal Aviation Administration approval of the MOTH rotorcraft, as well as approval by the U.S. Food and Drug Administration of Lung Biotechnology's xenotransplantation organ products.